With the help of physicians, pharmaceutical makers have made billions of dollars peddling medicines to treat attention deficit disorder, leading some experts, and even one pharmaceutical executive, to declare that the marketing push has gone too far.

Last year, sales of stimulant medication intended to treat attention deficit hyperactivity disorder (ADHD) reached $9 billion—a fivefold increase from a decade ago.